Personal tools

MCL coexpression mm9:134: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 3: Line 3:
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.139151649173176,0.131577193331716,0.163154637182541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.962873690222088,0.986859554433292,0.925318851623215,0,0.358556276484448,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.139151649173176,0.131577193331716,0.163154637182541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.962873690222088,0.986859554433292,0.925318851623215,0,0.358556276484448,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
|gostat_on_MCL_coexpression=GO:0030478;actin cap;0.0487659410724899;109624!GO:0004335;galactokinase activity;0.0487659410724899;69976!GO:0004957;prostaglandin E receptor activity;0.0487659410724899;19216!GO:0000318;protein-methionine-R-oxide reductase activity;0.0487659410724899;320183!GO:0030091;protein repair;0.0487659410724899;320183!GO:0030353;fibroblast growth factor receptor antagonist activity;0.0487659410724899;16181!GO:0005152;interleukin-1 receptor antagonist activity;0.0487659410724899;16181!GO:0048019;receptor antagonist activity;0.0487659410724899;16181!GO:0030547;receptor inhibitor activity;0.0487659410724899;16181!GO:0006012;galactose metabolic process;0.0487659410724899;69976!GO:0008083;growth factor activity;0.0487659410724899;16181,20256!
|gostat_on_MCL_coexpression=GO:0030478;actin cap;0.0487659410724899;109624!GO:0004335;galactokinase activity;0.0487659410724899;69976!GO:0004957;prostaglandin E receptor activity;0.0487659410724899;19216!GO:0000318;protein-methionine-R-oxide reductase activity;0.0487659410724899;320183!GO:0030091;protein repair;0.0487659410724899;320183!GO:0030353;fibroblast growth factor receptor antagonist activity;0.0487659410724899;16181!GO:0005152;interleukin-1 receptor antagonist activity;0.0487659410724899;16181!GO:0048019;receptor antagonist activity;0.0487659410724899;16181!GO:0030547;receptor inhibitor activity;0.0487659410724899;16181!GO:0006012;galactose metabolic process;0.0487659410724899;69976!GO:0008083;growth factor activity;0.0487659410724899;16181,20256!
|ontology_enrichment_celltype=CL:0000192!3.72e-37!3;CL:0000359!3.72e-37!3;CL:0002539!3.72e-37!3;CL:0000514!3.72e-37!3;CL:0000680!4.97e-19!6;CL:0000183!4.97e-19!6;CL:0000187!4.97e-19!6;CL:0000056!4.97e-19!6;CL:0000222!1.99e-16!7;CL:0000355!5.97e-13!9
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0001135!3.72e-37!3;UBERON:0004237!3.72e-37!3;UBERON:0004695!3.72e-37!3;UBERON:0002111!3.72e-37!3;UBERON:0004178!3.72e-37!3;UBERON:0000947!4.18e-28!4;UBERON:0001637!4.18e-28!4;UBERON:0004573!4.18e-28!4;UBERON:0003509!4.18e-28!4;UBERON:0004571!4.18e-28!4;UBERON:0010191!4.18e-28!4;UBERON:0004572!4.18e-28!4;UBERON:0000055!1.15e-22!5;UBERON:0007500!1.15e-22!5;UBERON:0001981!1.15e-22!5;UBERON:0002049!1.15e-22!5;UBERON:0007798!1.15e-22!5;UBERON:0004537!1.15e-22!5;UBERON:0006965!1.15e-22!5;UBERON:0001134!5.97e-13!9;UBERON:0002036!5.97e-13!9;UBERON:0002385!5.97e-13!9;UBERON:0000486!5.97e-13!9;UBERON:0007503!5.97e-13!9;UBERON:0001015!5.97e-13!9;UBERON:0002329!5.97e-13!9;UBERON:0003082!5.97e-13!9;UBERON:0003059!5.97e-13!9;UBERON:0007282!5.97e-13!9;UBERON:0004290!5.97e-13!9;UBERON:0009618!5.97e-13!9;UBERON:0000383!9.94e-12!10;UBERON:0007524!9.97e-11!11;UBERON:0003077!9.97e-11!11;UBERON:0007285!9.97e-11!11
}}
}}

Revision as of 16:44, 11 October 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr10:120219756..120219759,-p@chr10:120219756..120219759
-
Mm9::chr10:80811972..80811985,-p8@Hmg20b
Mm9::chr10:81027190..81027201,+p@chr10:81027190..81027201
+
Mm9::chr10:81059232..81059236,-p@chr10:81059232..81059236
-
Mm9::chr12:21218901..21218921,+p@chr12:21218901..21218921
+
Mm9::chr12:82253466..82253484,+p@chr12:82253466..82253484
+
Mm9::chr13:113836524..113836535,-p@chr13:113836524..113836535
-
Mm9::chr13:113836551..113836562,-p@chr13:113836551..113836562
-
Mm9::chr14:31694271..31694286,+p@chr14:31694271..31694286
+
Mm9::chr15:43002499..43002541,-p4@Rspo2
Mm9::chr15:43308759..43308816,+p1@Ttc35
Mm9::chr15:77426540..77426561,-p1@Apol10b
Mm9::chr15:78361517..78361546,+p@chr15:78361517..78361546
+
Mm9::chr16:23496331..23496334,-p@chr16:23496331..23496334
-
Mm9::chr16:25385975..25385989,+p@chr16:25385975..25385989
+
Mm9::chr16:25861275..25861283,+p@chr16:25861275..25861283
+
Mm9::chr17:45733606..45733615,-p@chr17:45733606..45733615
-
Mm9::chr17:45733657..45733669,-p@chr17:45733657..45733669
-
Mm9::chr17:54278109..54278116,+p@chr17:54278109..54278116
+
Mm9::chr18:39549074..39549085,-p1@ENSMUST00000135378
p1@uc008esw.1
Mm9::chr18:52718879..52718899,+p@chr18:52718879..52718899
+
Mm9::chr19:33182692..33182696,-p@chr19:33182692..33182696
-
Mm9::chr2:118655758..118655763,+p@chr2:118655758..118655763
+
Mm9::chr2:125719081..125719104,+p@chr2:125719081..125719104
+
Mm9::chr2:142663946..142663971,-p@chr2:142663946..142663971
-
Mm9::chr2:24176735..24176743,+p@chr2:24176735..24176743
+
Mm9::chr2:24192234..24192242,+p7@Il1rn
Mm9::chr2:24192366..24192387,+p1@Il1rn
Mm9::chr2:24204090..24204094,+p@chr2:24204090..24204094
+
Mm9::chr2:24204977..24204986,+p@chr2:24204977..24204986
+
Mm9::chr2:24205044..24205051,+p@chr2:24205044..24205051
+
Mm9::chr2:24205067..24205078,+p@chr2:24205067..24205078
+
Mm9::chr2:24205136..24205150,+p@chr2:24205136..24205150
+
Mm9::chr2:24205159..24205168,+p@chr2:24205159..24205168
+
Mm9::chr2:24205820..24205823,+p@chr2:24205820..24205823
+
Mm9::chr2:30575542..30575553,-p1@ENSMUST00000134755
Mm9::chr2:33610787..33610805,-p@chr2:33610787..33610805
-
Mm9::chr3:103539776..103539792,+p@chr3:103539776..103539792
+
Mm9::chr3:86343741..86343754,+p@chr3:86343741..86343754
+
Mm9::chr3:86343806..86343829,+p@chr3:86343806..86343829
+
Mm9::chr3:90407689..90407693,+p1@S100a4
Mm9::chr5:16375985..16375996,+p@chr5:16375985..16375996
+
Mm9::chr5:16376032..16376033,+p@chr5:16376032..16376033
+
Mm9::chr5:16376042..16376056,+p@chr5:16376042..16376056
+
Mm9::chr5:16376061..16376072,+p@chr5:16376061..16376072
+
Mm9::chr5:16376073..16376081,+p@chr5:16376073..16376081
+
Mm9::chr5:34890493..34890494,+p@chr5:34890493..34890494
+
Mm9::chr6:117123510..117123523,+p@chr6:117123510..117123523
+
Mm9::chr6:117123612..117123624,+p@chr6:117123612..117123624
+
Mm9::chr6:117123632..117123653,-p@chr6:117123632..117123653
-
Mm9::chr6:117123676..117123691,+p@chr6:117123676..117123691
+
Mm9::chr6:117123707..117123720,+p@chr6:117123707..117123720
+
Mm9::chr6:117123725..117123738,+p@chr6:117123725..117123738
+
Mm9::chr6:117123744..117123749,+p@chr6:117123744..117123749
+
Mm9::chr6:117123786..117123805,+p@chr6:117123786..117123805
+
Mm9::chr6:117123816..117123834,+p@chr6:117123816..117123834
+
Mm9::chr6:117123847..117123856,+p@chr6:117123847..117123856
+
Mm9::chr6:117123936..117123947,+p@chr6:117123936..117123947
+
Mm9::chr6:117124001..117124008,+p@chr6:117124001..117124008
+
Mm9::chr6:117124014..117124032,+p@chr6:117124014..117124032
+
Mm9::chr6:117124047..117124054,+p@chr6:117124047..117124054
+
Mm9::chr6:117124062..117124072,+p@chr6:117124062..117124072
+
Mm9::chr6:117124077..117124090,+p@chr6:117124077..117124090
+
Mm9::chr6:117124131..117124144,+p@chr6:117124131..117124144
+
Mm9::chr6:117124164..117124170,+p@chr6:117124164..117124170
+
Mm9::chr6:117124210..117124225,+p@chr6:117124210..117124225
+
Mm9::chr6:117124293..117124310,-p@chr6:117124293..117124310
-
Mm9::chr6:117124311..117124330,-p@chr6:117124311..117124330
-
Mm9::chr6:117124325..117124342,+p@chr6:117124325..117124342
+
Mm9::chr6:117124370..117124381,+p@chr6:117124370..117124381
+
Mm9::chr6:117124392..117124399,+p@chr6:117124392..117124399
+
Mm9::chr6:117124544..117124553,+p@chr6:117124544..117124553
+
Mm9::chr6:117124640..117124652,+p@chr6:117124640..117124652
+
Mm9::chr6:117124673..117124680,-p@chr6:117124673..117124680
-
Mm9::chr6:117129110..117129128,-p@chr6:117129110..117129128
-
Mm9::chr6:34548327..34548334,+p14@Cald1
Mm9::chr6:52183182..52183193,-p@chr6:52183182..52183193
-
Mm9::chr6:98292637..98292650,-p2@Gm765
Mm9::chr6:98292655..98292685,-p1@Gm765
Mm9::chr6:98292722..98292728,-p3@Gm765
Mm9::chr7:51562365..51562374,-p2@Clec11a
Mm9::chr8:73030018..73030042,-p5@2810428I15Rik
Mm9::chr8:73030245..73030275,-p2@2810428I15Rik
Mm9::chr8:86190726..86190781,+p1@Ptger1
Mm9::chr9:63045166..63045202,-p@chr9:63045166..63045202
-
Mm9::chrX:163612287..163612300,-p@chrX:163612287..163612300
-


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0030478actin cap0.0487659410724899
GO:0004335galactokinase activity0.0487659410724899
GO:0004957prostaglandin E receptor activity0.0487659410724899
GO:0000318protein-methionine-R-oxide reductase activity0.0487659410724899
GO:0030091protein repair0.0487659410724899
GO:0030353fibroblast growth factor receptor antagonist activity0.0487659410724899
GO:0005152interleukin-1 receptor antagonist activity0.0487659410724899
GO:0048019receptor antagonist activity0.0487659410724899
GO:0030547receptor inhibitor activity0.0487659410724899
GO:0006012galactose metabolic process0.0487659410724899
GO:0008083growth factor activity0.0487659410724899



Relative expression of the co-expression cluster over median <br>Analyst:




Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>

Uber Anatomy
Ontology termp-valuen
smooth muscle tissue3.72e-373
blood vessel smooth muscle3.72e-373
arterial system smooth muscle3.72e-373
artery smooth muscle tissue3.72e-373
aorta smooth muscle tissue3.72e-373
aorta4.18e-284
artery4.18e-284
systemic artery4.18e-284
arterial blood vessel4.18e-284
systemic arterial system4.18e-284
aortic system4.18e-284
arterial system4.18e-284
vessel1.15e-225
epithelial tube open at both ends1.15e-225
blood vessel1.15e-225
vasculature1.15e-225
vascular system1.15e-225
blood vasculature1.15e-225
vascular cord1.15e-225
skeletal muscle tissue5.97e-139
striated muscle tissue5.97e-139
muscle tissue5.97e-139
multilaminar epithelium5.97e-139
epithelial vesicle5.97e-139
musculature5.97e-139
somite5.97e-139
myotome5.97e-139
presomitic mesoderm5.97e-139
presumptive segmental plate5.97e-139
dermomyotome5.97e-139
trunk paraxial mesoderm5.97e-139
musculature of body9.94e-1210
dense mesenchyme tissue9.97e-1111
paraxial mesoderm9.97e-1111
presumptive paraxial mesoderm9.97e-1111


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=MCL_coexpression_mm9:134&oldid=2153443"